Report of Foreign Issuer (6-k)

---

 

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2019

 

_______________________

 

BioLineRx Ltd.

(Translation of Registrant’s name into English)

 

_______________________

 

2 HaMa’ayan Street
Modi’in 7177871, Israel

 (Address of Principal Executive Offices)

 

_______________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:        

 

Form 20-F ☑           Form 40-F ☐

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:          

 

Yes ☐           No ☑

 

---

On May 14, 2019, the Registrant will issue a press release announcing its financial results for the three months ended March 31, 2019. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of March 31, 2019 and for the three months then ended. Attached hereto are the following exhibits:

Exhibit 1: Registrant’s press release dated May 14, 2019;

 

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of March 31, 2019 and for the three months then ended; and

 

Exhibit 3 - Registrant’s operating and financial review as of March 31, 2019 and for the three months then ended.

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

 

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BioLineRx Ltd.   By: /s/ Philip Serlin Philip Serlin Chief Executive Officer
Dated: May 14, 2019

 

---